EBK HEALTH ECONOMICS AND POLICY
EBK HEALTH ECONOMICS AND POLICY
7th Edition
ISBN: 9781337668279
Author: Henderson
Publisher: YUZU
Question
Book Icon
Chapter 4, Problem 2QAP

(a)

To determine

The key screening strategies and the reason for them to be important than others.

(a)

Expert Solution
Check Mark

Explanation of Solution

  StrategyCostQALYSavedIncrementalCostIncrementalQALYIncrementalCERatio0.Noscreening500026.871.Papevery3yearstoage75682527.871825118252.HPVevery3yearstoage75695027.021250.85147.053.Papevery2yearstoage75727527.043250.02162504.Pap+HPVevery3yearstoage75740027.04125005.HPVevery2yearstoage75745027.0450006.Pap+HPVevery2yearstoage75792527.054750.0147500

  

As per the table, option 1, 3 and 6 could be considered as dominant options. In option 1 it is true that there is an incremental cost. Nevertheless, its QALY value is positive. Hence it could be considered as dominant. Further, in option 3, a positive QALY has been derived with an incremental cost that is considerably low. In option 6, both the tests could be done. However, the incremental cost involved does not seem alarming. Its QALY value is also a positive figure.

Economics Concept Introduction

Introduction:

When selecting between various treatment options, it is important to look into various measures that make them dominant. In this case, the cost of the treatment as well as the QALY value has been looked into. QALY or Quality Adjusted Life Year is a weighted average measure that takes into account both the qualitative and quantitative aspects of the burden of a disease. This is helpful in determining the level of medical intervention needed.

(b)

To determine

The incremental cost values, incremental QALY values and incremental cost effective ratios for the treatment options that seem to be economically rationale and state why they are so.

(b)

Expert Solution
Check Mark

Explanation of Solution

  StrategyCostQALYSavedIncrementalCostIncrementalQALYIncrementalCERatio0.Noscreening500026.871.Papevery3yearstoage75682527.871825118252.HPVevery3yearstoage75695027.021250.85147.053.Papevery2yearstoage75727527.043250.02162504.Pap+HPVevery3yearstoage75740027.04125005.HPVevery2yearstoage75745027.0450006.Pap+HPVevery2yearstoage75792527.054750.0147500

As per the table, option 3 and 6 seems to be economically rationale. Option 3 has an incremental value that is considerably low, together with a positive QALY value. Option 6 too consists of a somewhat lower incremental cost with a positive QALY value. Hence both these options could be considered as economically rational.

Economics Concept Introduction

Introduction:

In determining the economically rational treatment options out of a list, it is important to consider measures such as the incremental cost, incremental QALY and the incremental cost effectiveness ratio. An economically rational option would ideally have a lower incremental cost and a positive QALY value.

(c)

To determine

The best strategy to be recommended from a standpoint of public health.

(c)

Expert Solution
Check Mark

Explanation of Solution

  StrategyCostQALYSavedIncrementalCostIncrementalQALYIncrementalCERatio0.Noscreening500026.871.Papevery3yearstoage75682527.871825118252.HPVevery3yearstoage75695027.021250.85147.053.Papevery2yearstoage75727527.043250.02162504.Pap+HPVevery3yearstoage75740027.04125005.HPVevery2yearstoage75745027.0450006.Pap+HPVevery2yearstoage75792527.054750.0147500

As per the table, option 6 could be considered the best strategy to be recommended from a public health standpoint. The option included both the tests Pap and HPV, with a reasonable incremental cost as well as a positive QALY value. Hence it could be recommended as the best strategy.

Economics Concept Introduction

Introduction:

When recommending health strategies from the perspective of public health, it is important that they address to the needs of a wider population, at a lower cost. In this regard, out of the strategy options given, the one with a considerably low incremental cost together with a positive QALY value must be selected.

Want to see more full solutions like this?

Subscribe now to access step-by-step solutions to millions of textbook problems written by subject matter experts!
Students have asked these similar questions
An article in JAMA by Mandelblatt et al (2002) compared the societal costs and benefits of human papillomavirus (HPV) testing, Pap testing, and their combination to screen for cervical cancer. The paper studied 18 different population screening strategies – Pap testing alone, HPV testing alone, and Pap plus HPV testing – every 2 or 3 years for women beginning at age 20 and continuing to 65 years, 75 years, and death.  The following table summarizes some of the results (low cost to high cost).  Costs include screening and treatment costs, discounted over the individual’s expected lifetime.   Strategy Cost ($) QALYs Saved Incremental Cost Incremental QALY ICER* 0. No screening 5,000 26.87       1. Pap every 3 years to age 75 6,825 27.02       2. HPV every 3 years to age 75 6,950 27.02       3. Pap every 2 years to age 75 7,275 27.04       4. Pap + HPV every 3 years to age 75 7,400 27.04       5. HPV every 2 years to age 75 7,450…
While it may seem intuitively obvious that health expenditures will increase as a population age – older people, after all, are less healthy on average than younger people – in fact, several prominent health economists have argued that it is not ageing per se, but rather some of the correlates of an ageing population that cause health expenditures to rise as population ages. For instance, Getzen (1992) argues that, at least in part, rising health expenditures with an ageing population are due to the higher incomes and resources of the older population; health care is a normal good, so higher incomes lead to higher expenditures. In a similar manner, Zweifel et al. (1999) argue that the real problem with an ageing population, at least as far as health care costs are concerned, is that there will be more people who are within a couple of years of dying. Since health care expenditures rise sharply close to the end of life, it is this, rather than population ageing by itself, that leads to…
Suppose you are currently (i.e. 2024) performing a cost-effectiveness analysis and you wish to include the cost per visit of a hospital admission for an acute ischemic stroke in a patient without major complications or comorbidities in your analysis. The Agency for Healthcare Research and Quality's HCUP National Inpatient Sample online database reports the following information for 2015: 2015 National Medicare-Severity Diagnosis Related Groups (MS-DRG): #063 Acute ischemic stroke w use of thrombolytic agent w/o cc/mcc Number Total number of discharges: N All discharges + Rate Rate of discharges per 100,000 persons 2.2 Length of stay LOS (length of stay), days (mean) 3.0 LOS (length of stay), days (median) 3.0 Hospital charges Charges, $ (mean) 63,243 Hospital costs Costs, $ (mean) 15,239 + Due to the transition from ICD-9-CM to ICD-10-CM in October 2015, these 2015 statistics were calculated using only quarter 1-3 data, and the statistics available are limited What would you use for…
Knowledge Booster
Background pattern image
Similar questions
SEE MORE QUESTIONS
Recommended textbooks for you
Text book image
EBK HEALTH ECONOMICS AND POLICY
Economics
ISBN:9781337668279
Author:Henderson
Publisher:YUZU